What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?

Thursday, Vor Biopharma Inc. VOR announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory acute myeloid leukemia (AML) receiving trem-cel followed by Mylotarg. Pfizer Inc's PFE Mylotarg is indicated for newly diagnosed CD33-positive AML in adults and relapsed or refractory AML CD33-positive acute myeloid leukemia in adults and pediatric patients two years and older. The data demonstrated reliable engraftment, shielding from Mylotarg on-target toxicity, a broad ...